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Objective: To assess the prevalence and distribution of medically unexplained painful somatic 
symptoms (PSSs) versus nonpainful somatic symptoms (NPSSs) in patients diagnosed with 
major depressive episode (MDE).
Method: A total of 571 outpatients diagnosed with MDE according to DSM-IV-TR criteria 
were consecutively enrolled into a cross-sectional, multicentric, observational study over a 
period of 7 months. Subjects were evaluated by means of the ad hoc validated 30-item Somatic 
  Symptoms Checklist (SSCL-30) and Zung’s questionnaires for depression and anxiety. The 
32-item   Hypomania Checklist (HCL-32) was also administered in order to explore any eventual 
association of PSSs or NPSSs with sub-threshold (DSM-IV-TR [Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, Text Revision] not recognized) bipolar disorder (BD).
Results: In our sample, just 183 patients (32%) did not report painful somatic symptoms 
(NPSSs). Of these, 90 patients (15.76%) had no somatic symptoms at all. The remaining 388 
(68%) had at least one PSS being subdivided as follows: 248 (43%) had one or two PSSs, while 
140 (25%) experienced two or more. Patients with at least one PSS also reported a greater 
number of nonpainful somatic symptoms than NPSS. Bipolar patients (associated with higher 
HCL-32 scores) were less represented across PSS cases than NPSS subjects. Conversely, 
females were more prone to having a higher number of total somatic symptoms (and bipolar 
features).
Conclusion: PSSs are common in patients with MDE, especially among those patients report-
ing fewer somatic symptoms in general as opposed to those patients who exhibit more somatic 
symptoms (both PSSs and NPSSs) with lower relative number of PSSs. A major therapeutic 
implication is that antidepressant monotherapy could be used with more confidence in unex-
plained PSS patients than in NPSS patients because of the latter group’s lower frequency of 
(sub)-threshold bipolar features.
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Introduction
Major depressive episode (MDE) represents a multidimensional condition possibly 
exhibiting with a wide range of clinical pictures. Frequently, clinical presenta-
tions may include the presence of painful (PSSs) as well as nonpainful somatic 
  symptoms (NPSSs).1 Nonetheless, somatic symptoms in the course of MDE often go 
  underestimated2 despite their impact on the course of illness and treatment choices. 
In fact, when   inappropriately recognized and treated, (medically unexplained) 
somatic symptoms – considered as symptoms otherwise not referable to nonpsy-
chiatric   disturbances – are associated with poor prognosis, higher risk for residual Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  symptomatology, as well as increased risk for relapse and 
recurrence.3–6 Hence, the need for their appreciation and 
proper recognition is unquestionable. Furthermore, MDE 
could frequently represent the main or even the only mani-
festation of bipolar disorder (BD) lasting for many years prior 
to the onset of frank (hypo)-mania. Thus, the importance of 
early appropriate recognition and management of depressive 
features, eventually pointing out a bipolar diathesis, should 
be considered mandatory in order to reduce the chance of 
iatrogenic effects as the antidepressant-induced resistance to 
treatment or cyclicity of the disorder.7
The aim of the present study is to assess the distribution of 
PSSs and NPSSs on MDE (including both single and recur-
rent episodes) and to explore their possible association with 
bipolarity assessed according to Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision 
[DSM-IV-TR] criteria (full-threshold BD) and with the 
32-item Hypomania Checklist (HCL-32) rating scale8 (for 
sub-threshold bipolarity).
Methods
The present study is based on a post-hoc partial analysis of 
the database collected for a previous study, including 571 
consecutive patients with a diagnosis of MDE, according to 
DSM-IV-TR, that were enrolled in a large cross-sectional, 
multicentre, observational study (COME TO ME).9 The 
study involved 30 psychiatric outpatient facilities, distributed 
throughout Italy, investigating the prevalence of medically 
unexplained somatic symptoms in the course of MDE, which 
resulted in severe depressive symptomatology, high rates of 
misdiagnosis, and improper treatment and health resource 
utilization.
According to the observational nature of the protocol, 
routine medical procedures were not modified. The   Ethics 
Committee of each center approved the study protocol in 
compliance with the Italian Ministerial Bulletin issued on 
  September 2, 2002 regarding observational studies. All 
patients gave their informed consent concerning handling and 
use of the data collected during the course of the study. Finally, 
the study was sponsored by Boehringer Ingelheim, Italy.
Study population
Subjects referred to the selected centers between December 
2006 and July 2007 were screened for inclusion in the study. 
Patients were recruited consecutively, according to the fol-
lowing inclusion criteria: 1) both genders, aged 18–75 years; 
2) diagnosis of major depressive episode according to 
DSM-IV-TR (major depressive disorder, recurrent major 
depression, depressive episode in course of type I and II 
bipolar disorder, depression not otherwise specified (NOS); 
and 3) ability to complete the self- and hetero-administered 
questionnaires. The exclusion criteria were: 1) comorbidity 
with schizophrenia and other psychotic disturbances, and 
2) current relevant physical illnesses.
The study included 571 depressed outpatients; 8 (1.4%) 
of them had incomplete information on demographic and 
clinical variables. The study population therefore consisted 
of 563 eligible subjects, with a mean number of patients of 
18.7 (range 5–56) for each center; 376 subjects (66.8%) were 
females and 187 (33.2%) males; 251 subjects (44.5%) were 
aged 18–50 years, and 313 (55.5%) aged over 50, with mean 
age of 51 (standard deviation = 13). The level of education 
was higher than 11 years for 245 (43.5%) patients, and most 
of them (n = 331, 58.8%) were married.
Diagnostic procedure and symptom 
assessment
Individuals were assessed by psychiatrists with extensive 
clinical experience in the diagnosis and treatment of mood 
disorders. Diagnosis of MDE (major depressive disorder, 
recurrent major depression, depressive episode type I and II 
bipolar disorder; depression NOS) was made according to 
DSM-IV-TR criteria.
An anonymous datasheet was used to collect the fol-
lowing information: demographic status, lifestyle, surgical, 
pathological, and pharmacological case history, presence and 
characterization of somatic symptoms and related delay in 
major depression diagnosis and treatment, and consump-
tion of health resources within the 6 months preceding 
enrollment. All of the information was gathered directly by 
the patient with the help of significant others and medical 
records.
HCL-328 was administered for the evaluation of lifetime 
manic or hypomanic features, and severity of depressive and 
anxious symptomatology was self-evaluated by means of the 
Zung’s questionnaires for depression and anxiety.10,11
Statistical analysis
Comparative analysis for familial, epidemiological, clinical, 
and course characteristics of subgroups were conducted 
using the Student’s t-test for the dimensional variables 
  (Mann–Whitney U-test, when appropriate) and the chi-square 
analysis for those categories (Fisher exact-test, when appro-
priate). We used a Bonferroni’s significance of P = 0.001 level 
corrected for multiple comparisons. Given the exploratory 
nature of the study, we set significance at level of 0.5, two Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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tailed, in order to detect potentially clinically meaningful 
associations.
Results
Among the 571 MDE outpatients of our sample, only 183 
patients (32%) did not report unexplained PSS (NPSSs), 
including 90 subjects (15.76%) who reported no somatic 
symptoms at all. The other 388 (68%) patients had at least 
one PSS. Among this latter group, 248 (43%) had one or 
two, while 140 (25%) experienced two or more. The patients 
with at least one PSS who also reported associated NPSSs 
also showed a higher total number of NPSSs compared with 
the patients without PSSs, with a mean NPSSs number of 
4.3 ± 3.3 versus 2.3 ± 1.7 (t = 9.2, P = 0.0001).
Headache was the most frequently reported PSS (n = 220, 
38.5%), followed by osteo-articular pain (n = 200, 35%), and 
gastralgia (n = 102, 17.9%); concerning NPSSs, asthenia was 
the far more represented symptom (n = 368, 64.4%), followed 
by insomnia (n = 237, 41.5%), tenseness (n = 227, 39.8), palpi-
tations (n = 190, 33.3%), dizziness (n = 114, 20%), decreased 
libido (n = 108, 19%), tremor (n = 108, 19%), decreased appe-
tite (n = 105, 18.4%), constipation (n = 89, 15.6%), dyspnea 
(n = 89, 15.6%), and sweating (n = 86, 15.1) (Table 1).
Comparing the three groups (NPSS, one or two PSSs, 
and three or more PSSs), no differences were found con-
cerning demographic features except for gender distribution. 
Females were more represented among patients with two or 
more PSSs, compared with groups with one PSS and NPSS 
(Table 2).
Concerning diagnostic distribution, bipolar depression 
was more frequent among patients with NPSS than in patients 
with PSSs (P = 0.001); also, the higher the number of PSSs, 
the lower the chance of bipolar diagnosis.
In contrast, depression NOS showed an inverse trend. 
As expected, Zung’s depression and anxiety scores greater 
than 50 were more represented among the group of patients 
with three or more PSSs than in the other two groups. 
  Remarkably, patients with three or more PSSs were less 
frequently represented among those having an HCL-32 total 
score greater than 14 (the cutoff diagnostic value), while a 
HCL-32 total score lower than 14 was more associated with 
NPSSs (Table 2).
Discussion
In interpreting our results, some methodological limitations 
must first be taken into account. Although recorded, phar-
macological treatments were not considered as potentially 
  influencing the perception of somatic pain. Yet, it must be noted 
that they might have influenced the pharmacological choices 
of the therapist. As expected, somatic symptoms were a fre-
quent finding in the course of depression, especially for female 
patients. Nonetheless, avoidance of a systematic recording of 
the clinical history of the subjects might have further limited 
the validity of our results. This seems particularly true concern-
ing the lack of information about the number and severity of 
previous episodes, if any, and the eventual presence of previous 
hospitalizations and/or suicidal attempts. Also, the anxiety/
depression scores appear driven by endorsing the somatic 
items in the SSCL-30 scale, thus limiting the reliability of this 
finding, especially considering the absence of accurate records 
of anxious comorbidities (ie, somatoform disorder).
The fact that medically unexplained somatic complaints 
were essentially not associated with bipolarity is also 
a remarkable result since it was initially expected to be related 
Table 1 Medically unexplained somatic symptoms in 571 major 
depressed patients: frequency distribution
Symptoma N %
PSSs
  3. Headache 220 38.5
13. Osteoarticular pain 200 35.0
17. Gastralgia 102 17.9
  9. Dyspepsia 83 14.5
12. Abdominal pain 75 13.1
15. Transient pain 68 11.9
  7. Dysphagia 41 7.2
14. Chest pain 41 7.2
21. Itching 36 6.3
11. Dysuria 22 3.9
  8. Dysmenorrhea 18 3.2
NPSSs
  2. Asthenia 368 64.4
19. Insomnia 237 41.5
25. Tenseness 227 39.8
20. Palpitations 190 33.3
30. Dizziness 114 20.0
  6. Decreased libido 108 18.9
27. Tremor 108 18.9
18. Decreased appetite 105 18.4
  4. Constipation 89 15.6
10. Dyspnea 89 15.6
24. Sweating 86 15.1
23. Drowsiness 78 13.7
29. Flushing 77 13.5
  1. Aerophagia 61 10.7
28. Tenesmus 53 9.3
  5. Diarrhea 37 6.5
16. Flatulence 35 6.1
26. Cough 26 4.6
22. Hiccups 10 1.9
Note: aThe numbers refer to the items of the SSCL-30 scale.
Abbreviations: NPSS, painless somatic symptoms; PSS, painful somatic symptoms; 
SSCL-30, 30-item Somatic Symptoms Checklist.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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to the “excitement” of mania. Rather, the total number of 
somatic symptoms (including both PSSs and NPSSs) was 
higher among those with a bipolar diagnosis. These findings 
indicate that PSSs could be less represented in “bipolar” 
(HCL-32 total score $ 14) MDEs rather than unipolar MDEs. 
A major therapeutic implication is that antidepressant mono-
therapy could be used with more confidence in unexplained 
PSS patients than in NPSS patients because of the latter 
group’s lower frequency of (sub)-threshold bipolar features. 
Specifically, the use of SNRIs (serotonin norepinephrine 
reuptake inhibitors) or the choice of tricyclic antidepres-
sants (TCAs), especially the more pro-norepinephrinergic 
secondary amines, may be preferred as hypothetically more 
somatic-symptoms-oriented therapies for those with PSSs 
(found to have also a higher total number of somatic symp-
toms in general). Furthermore, TCAs and SNRIs might be 
less prone to induce (hypo) manic switches in PSS patients 
compared with (bipolar) NPSSs.
Finally, stating the strong limits of our exploration, fur-
ther longitudinal, more accurate investigations are needed in 
order to confirm this merely preliminary report.
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